Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
Crizotinib Continues to Show Promise for Some Lung Tumors, Faces Challenge of Drug Resistance
(Posted: 12/07/2010) - New data from a phase I trial of crizotinib, a small-molecule drug that targets cancer-causing chromosomal rearrangements involving the gene ALK, in patients with non-small cell lung cancer add to positive results published October 28, 2010, in the New England Journal of Medicine.
Romidepsin Reduces Disease Burden and Skin Symptoms in Patients with Previously Treated Cutaneous T-Cell Lymphoma
(Posted: 11/08/2010) - Clinical trial results published October 10, 2010, in The Journal of Clinical Oncology, show that romidepsin (Istodax®), a type of targeted therapy called a histone deacetylase inhibitor, reduced the symptoms and tumor burden of cutaneous T-cell lymphoma in many patients with advanced disease.
Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
(Posted: 06/19/2009, Updated: 11/05/2010) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.
Rituximab Improves Outcomes for Patients With Chronic Lymphocytic Leukemia
(Posted: 01/14/2009, Updated: 11/05/2010) - Advanced chronic lymphocytic leukemia patients who received the monoclonal antibody rituximab in addition to standard chemotherapy with fludarabine and cyclophosphamide (FC) had outcomes far better than those patients who received FC alone, according to studies presented December 2008 at the American Society of Hematology meeting.
New Drug Benefits Patients with Advanced Prostate Cancer
(Updated: 11/05/2010) - The drug cabazitaxel improves the survival of some patients with advanced prostate cancer compared with those who receive standard chemotherapy.
(Posted: 12/07/2010) - New data from a phase I trial of crizotinib, a small-molecule drug that targets cancer-causing chromosomal rearrangements involving the gene ALK, in patients with non-small cell lung cancer add to positive results published October 28, 2010, in the New England Journal of Medicine.
Romidepsin Reduces Disease Burden and Skin Symptoms in Patients with Previously Treated Cutaneous T-Cell Lymphoma
(Posted: 11/08/2010) - Clinical trial results published October 10, 2010, in The Journal of Clinical Oncology, show that romidepsin (Istodax®), a type of targeted therapy called a histone deacetylase inhibitor, reduced the symptoms and tumor burden of cutaneous T-cell lymphoma in many patients with advanced disease.
Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
(Posted: 06/19/2009, Updated: 11/05/2010) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.
Rituximab Improves Outcomes for Patients With Chronic Lymphocytic Leukemia
(Posted: 01/14/2009, Updated: 11/05/2010) - Advanced chronic lymphocytic leukemia patients who received the monoclonal antibody rituximab in addition to standard chemotherapy with fludarabine and cyclophosphamide (FC) had outcomes far better than those patients who received FC alone, according to studies presented December 2008 at the American Society of Hematology meeting.
New Drug Benefits Patients with Advanced Prostate Cancer
(Updated: 11/05/2010) - The drug cabazitaxel improves the survival of some patients with advanced prostate cancer compared with those who receive standard chemotherapy.
